During the past decade, Centre Hospitalier Universitaire Hassan II conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier Universitaire Hassan II" are "Carcinoma, Non-Small-Cell Lung" (1 trials), "Esophageal Squamous Cell Carcinoma" (1 trials), "Progressive Multiple Sclerosis (PMS)" (1 trials) and "Triple Negative Breast Neoplasms" (1 trials). Many other conditions were trialed in "Centre Hospitalier Universitaire Hassan II" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier Universitaire Hassan II" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Atezolizumab Matching Placebo" (1 trials), "Capecitabine" (1 trials), "Carboplatin" (1 trials) and "Gemcitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier Universitaire Hassan II" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Centre Hospitalier Universitaire Hassan II". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centre Hospitalier Universitaire Hassan II, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier Universitaire Hassan II, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".